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Abstract
Forty-ﬁve days after the ﬁrst conﬁrmed and fatal Crimean–Congo haemorrhagic fever (CCHF) case in Greece in 2008, a female patient
with similar signs and symptoms (high fever, thrombocytopaenia) and resident of the same area, was admitted to the University General
Hospital of Alexandroupolis. Before admission, she had visited a local hospital where a cephalosporin was prescribed. A rash manifested
over subsequent days, which was misdiagnosed as an allergy to the drug. Upon admission to the University Hospital, she was given fur-
ther antibiotics, including doxycycline; a few hours later, ribavirin was added because CCHF was suspected. After the patient’s death,
rickettsiosis caused by Rickettsia conorii conorii (Meditteranean spotted fever; MSF) was diagnosed. Extremely high values of interleukin
(IL)-1ra, IL-6, interferon-c-inducible protein-10, monocyte chemoattractant protein-1 and an absence of tumour necrosis factor-a were
observed. MSF is a potentially severe and even fatal disease resembling viral haemorrhagic fevers that has to be included in the differen-
tial diagnosis of febrile syndromes combined with thrombocytopaenia, even when a tick bite is not reported, and an eschar is absent.
Physicians have to be aware of MSF in patients with severe disease who are returning from the Mediterranean area.
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Introduction
Mediterranean spotted fever (MSF) is a tick-borne disease
caused by Rickettsia conorii conorii [1]. After an asymptomatic
incubation of 6–7 days, the onset of MSF is abrupt and typical
cases present with high fever (39C), inﬂuenza-like symptoms,
a maculopapular erythematous rash, and a black eschar (tache
noire) at the tick bite site. MSF is endemic in the Mediterranean
area, including northern Africa and southern Europe. In Eur-
ope, cases are encountered in late spring and summer, when
the tick vectors (mainly the brown dog tick, Rhipicephalus san-
guineous) are most active. The highest annual incidence was
observed in Portugal, with 9.8 cases per 100 000 persons [2].
A high incidence is correlated with high temperatures and low
rainfalls, and decreased numbers of frosty days during the
preceding years. Recently, it was shown that the afﬁnity of
R. sanguineus for humans is increased in warmer temperatures
when the ticks are more aggressive and attack humans more
often; thus, it has been predicted that, because of the global
warming, more pathogens transmitted by R. sanguineus may
emerge [3]. Risk factors for severe forms of MSF include
advanced age, immunocompromised condition, chronic alco-
holism, glucose-6-phosphate dehydrogenase deﬁciency, prior
inappropriate prescription of an antibiotic, delay of treatment
and diabetes [4]. MSF has been considered a mild disease, with
mortality rates of 1–3%; however, the overall case-fatality
rates appear to differ depending on the region and the time
period. Thus, mortality rates of 3.2% have been reported in
Algeria in 2004, 5.6% in France in 2003, and 32.3% in hospital-
ized patients in Portugal in 1997, where it was found that the
risk of fatal outcome was signiﬁcantly higher in those who pre-
sented with diabetes, vomiting, dehydration and uraemia [2,4].
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MSF cases have been reported in Greece, and R. conorii
has been isolated both from patients and ticks [5–9].
However, the disease is likely to be underestimated in this
country and diagnosis is based mainly on clinical symptoms
or only on serology. In a serosurvey conducted in Northern
Greece, antibodies to R. conori were detected in 7.9% of the
human population [10]. Here, we present a fatal MSF case in
Northern Greece, which was initially considered to be one
of Crimean–Congo haemorrhagic fever (CCHF): ﬁrst,
because the symptoms strongly resembled those of severe
haemorrhagic fever and, second, because it was observed in
the same region where the ﬁrst conﬁrmed Greek CCHF
case was described, 45 days before [11], thus fulﬁlling the
case deﬁnition for a probable CCHF case [12].
Case Report
In August 2008, a 62-year-old, previously healthy woman was
admitted to the University General Hospital of Alexandrou-
polis, with a 1-week (day 7) fever (39.5C), accompanied by
a stiff neck, stupor and a maculopapular rash on the trunk
and the extremities; she presented haematomas in mucus
membranes and at sites of injection. The patient was engaged
in agricultural activities in a small town, 14 km east of Komo-
tini, in north-eastern Greece. The small town is located at
an altitude of 32 m, next to the feet of the Rhodope moun-
tains (latitude 414¢53¢¢N, longitude 2512¢29¢¢E). The patient
did not report any travel abroad or any tick bite. Before
admission (day 2), she had visited the local hospital where
a cephalosporin was prescribed. As she presented with a
maculopapular rash, she visited the hospital again (day 4),
where a low platelet count was found (77 000/lL). An
allergy to cephalosporin was suspected, the drug was discon-
tinued, and she was advised to come back to the hospital
after 3 days for re-examination. The patient felt severely ill,
with high fever, and was admitted to the Hospital of
Alexandroupolis (day 7).
The main laboratory ﬁndings on admission were: leuco-
cytes, 6600/lL with 86.8% neutrophils; haematocrit, 26.4%;
platelets, 34 · 109/L; prolonged activated partial thrombo-
plastin time (35.8 s) and elevated levels of serum transamin-
ases (aspartate transaminase, 144 IU/L; alanine transaminase,
99 IU/L); gamma-glutamyl transpeptidase, 186 IU/L; lactic
dehydrogenase, 389 IU/L; International Normalized Ratio,
1.43, and D-dimers more than 5000 ng/mL. Cerebrospinal
ﬂuid (CSF) analysis revealed 20 leucocytes and 700 erythro-
cytes/mm3, glucose 48 mg/dL, and protein 54 mg/dL. Chest
X-ray and brain computed tomography (CT) did not reveal
any abnormality. The CT scan of the abdomen revealed
severe ascites under pressure in the whole peritoneum and
liver enlargement, as well as remarkable oedema surrounding
the whole portal vein. A CSF culture was negative for com-
mon pathogens. The day of admission to the hospital (day 7),
she was given penicillin G intravenously (i.v.), amikacin i.v.,
ciproﬂoxacin i.v. and doxycycline per os. Because of the simi-
larity of the symptoms and ﬁndings with those of the fatal
CCHF case observed 45 days before, CCHF was suspected
and, a few hours later, ribavirin per os was administered,
when preventive measures for probable nosocomial or family
transmission were implemented. The patient’s condition
deteriorated rapidly, prompting the transfer to the intensive
care unit (day 8), where she was intubated and mechanically
ventilated. Apart from supportive therapy with ﬂuids, inotro-
pic agents, blood and plasma were given, as well as vancomy-
cin and meropenem. The number of white blood cells
increased to 12 000/lL. The lactate level, at 4.7 mEq/dL on
admission to the hospital, increased to 5.9 mEq/dL on admis-
sion to the intensive care unit and to >15 mEq/dL 5 h later.
The patient developed convulsions. On day 9, the patient
died with multiple organ failure. Perivascular haemorrhages
in all organs were seen at autopsy.
Laboratory Diagnosis
A serum sample taken from the patient upon admission was
sent to the First Department of Microbiology at Aristotle
University of Thessaloniki. Because CCHF was initially sus-
pected, the sample was tested by serology and RT-PCR for
CCHFV infection and found to be negative. The sample was
then tested using serological and molecular methods for
hantavirus infection and leptospirosis because both diseases
are endemic in Greece; they also yielded negative results.
Subsequently, the sample was tested for rickettsial IgM and
IgG antibodies; no IgM antibodies were detected, whereas a
titre of 128 for IgG antibodies against R. conorii was
observed. Positive results were obtained with the use of
PCRs that amplify a 360-bp fragment of the 17-kDa antigen
gene [13], and a 632-bp fragment of the ompA gene [14]. All
PCR products were sequenced, allowing postmortem identi-
ﬁcation of the causative pathogen as R. conorii conorii (the
sequences of both genes were identical with the available
published sequences from R. conorii strain Malish 7) [6].
R. conorii was never isolated or detected in our laboratory,
thus excluding the possibility of contamination.
To investigate the host innate immune response, we mea-
sured simultaneously 27 cytokines, chemokines and growth
factors in the patient’s serum by using the BioPlex Human
Cytokine 27-plex panel in a Bio-plex suspension array system
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(Bio-Rad Laboratories, Inc., Foster City, CA, USA). The
panel included interleukin (IL)-1b, IL-1 receptor antagonist
(IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12,
IL-13, IL-17, eotaxin, ﬁbroplast growth factor, granulocyte
colony-stimulating factor (G-CSF), granulocyte-macrophage
colony-stimulating factor, interferon (IFN)-c, interferon-c-
inducible protein 10 (IP-10), monocyte chemoattractant
protein (MCP)-1, macrophage inﬂammatory protein (MIP)-1a,
MIP-1b, platelet-derived growth factor (PDGF)-bb, RANTES,
tumour necrosis factor (TNF)a and vascular endothelial
growth factor (VEGF). A strong innate immune response
was observed, including increased expression of IL-6
(832 pg/mL), IL-8 (158 pg/mL), IL-9 (116 pg/mL), IL-10
(49 pg/mL), IL-15 (58 pg/mL), IL-1ra (4441 pg/mL), RANTES
(1835 pg/mL), eotaxin (45 pg/mL), G-CSF (346 pg/mL), IFN-c
(437 pg/mL), MCP-1 (1140 pg/mL), MIP-1b (673 pg/mL),
PDGF (3371 pg/mL), VEGF (103 pg/mL), and IP-10 (8000 pg/
mL), whereas TNFa was not detected.
Discussion
R. conorii was ﬁrst isolated and identiﬁed from R. sanguineous
ticks in 2003 in Greece [5], whereas, in 2005, the isolation
of a R. conorii Malish 7 strain from a febrile patient with an
eschar and maculopapular rash was reported [6]. Although
the patient in the present study did not notice any tick bite,
she was engaged in cutting bushes in a ﬁeld covered by wild
vegetation, where rodent carcasses were present. The role
of rodents as probable reservoirs for R. conorii has not yet
been clariﬁed; however, it is considered that dogs do not
appear to be an efﬁcient reservoir, whereas, most probably,
other mammals, including small rodents, are implicated.
A variety of factors play a role in the severity of MSF;
however, as in haemorrhagic fevers, vascular permeability is
the main pathophysiological effect. Recently, it was shown
that mild/moderate MSF is associated with a strong and bal-
anced intralesional proinﬂammatory and anti-inﬂammatory
response, with a dominant type 1 immunity, whereas severe
MSF is associated with increased expression of chemokine
mRNA [15]. In another study, it was found that R. conorii
induced a marked increase in MCP-1, IL-8, and adhesion mol-
ecules in endothelial cells, involving toll-like receptor 4 acti-
vation [16]. In the present study, extremely high values of
IL-1ra, IL-6, IP-10 and MCP-1 combined with the absence of
TNFa are of interest, but further studies are needed in more
patients for a comparison between mild and severe forms of
the disease. Most probably, the initiation of the cytokine
cascade is the major factor related ot the severity and
outcome of the disease and has to be further elucidated.
The present fatal MSF case presented epidemiological
characteristics, clinical symptoms and laboratory ﬁndings sim-
ilar to those of the fatal CCHF case. The absence of an
eschar, the probable but unnoticed tick bite, or other lesions
on the patient’s body, led to misdiagnosis, in addition to the
initial consideration of the rash as an allergic effect. In a
recent study of Albanian patients with suspected CCHF,
CCHF virus was detected in 38.2% of cases, hantaviruses in
11.7%, and leptospirosis and rickettsiosis were diagnosed in
29.4% and 2.9% of cases, respectively, thereby establishing
the diagnosis in 82.2% of the cases [17]. Because the
application of molecular methods is very helpful for a rapid
diagnosis, proper samples of patients with febrile thrombocy-
topaenia have to be sent as soon as possible to reference
laboratories, and empirical tetracycline therapy is advisable.
MSF is a potentially severe and even fatal disease; it there-
fore has to be included in the differential diagnosis of febrile
syndromes with thrombocytopaenia, even when a tick bite is
not reported, and even when an eschar is absent, whereas a
rash, representing a hallmark of rickettsial diseases, has to be
carefully evaluated. Physicians of other countries have to
be aware of MSF in patients with severe disease who are
returning from the Mediterranean area.
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